Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Macrophages play a pivotal role in a host's defence against pulmonary infections. Macrophage functions are impaired in immunosuppressed (IS) patients, regardless of whether they are HIV-positive (HIV+) or -negative (HIV-). Several studies have indicated that
urokinase plasminogen activator
(
uPA
) and transforming growth factor beta (TGF-beta) are important factors in a host's defence against pulmonary pathogens. We measured
uPA
and TGF-beta activity in unstimulated peripheral blood monocytes (PBM) of both HIV-infected and non-infected IS patients with or without Pneumocystis jiroveci (formerly carinii) pneumonia (
PCP
). As previously found in alveolar macrophages (AMs), the majority of
uPA
activity was found in cell lysates. The highest values of
uPA
activity were found in control subjects. All the patients displayed a decreased production of
uPA
, irrespective of HIV infection. Similarly, active TGF-beta was higher in control subjects than in HIV+ and IS patients. The presence of P. jiroveci infection further lowered
uPA
and TGF-beta activity. Decreased TGF-beta activation might be a consequence of lower
uPA
production, which may, in turn, influence virus replication, since it has been demonstrated that TGF-beta can suppress human HIV expression in monocytes/macrophages. Further studies are warranted to elucidate whether the decrease in
uPA
and TGF-beta activity impairs a host's defence against P. jiroveci infection.
...
PMID:Urokinase plasminogen activator and TGF-beta production in immunosuppressed patients with and without P. Jiroveci infection. 1670 17